Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
bifidobacterium longum CCFM1113
- Development stage
- Preclinical
- Lead developer
- Jiangnan University
- Modality
- Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
- Administration
- Oral
01
Overview
Bifidobacterium longum CCFM1113 (also known as B. longum subsp. longum CCFM1113) is a probiotic bacterial strain developed by researchers at Jiangnan University and maintained in the Culture Collection of Food Microorganisms (CCFM). It is currently under investigation as a live biotherapeutic product for the treatment of constipation. The strain's therapeutic effect is attributed to its ability to produce acetic acid, which promotes the repair of the intestinal mechanical and immune barriers. Furthermore, CCFM1113 has been shown to inhibit the secretion of aquaporin 8 (AQP8), a water channel protein, thereby decreasing intestinal water reabsorption and maintaining stool moisture. It has also been studied in combination with other strains, such as Bifidobacterium bifidum CCFM1167, to enhance its efficacy in restoring gut barrier function.
- Other names
- Bifidobacterium longum subsp. longum CCFM1113长双歧杆菌CCFM1113
02
Targets
AQP8 (Aquaporin-8)
Beyond the preview
Go deeper on bifidobacterium longum CCFM1113.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on bifidobacterium longum CCFM1113.